Search CFOR
CapForce Inc.
OTC · CIK 1293818
Last close4.04
Daily change+0.00 (0.00%)
10 Years gain-100.00%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
CFOR · STANDARD
SIC 8071 · Services-Medical Laboratories · Fiscal year end 1231
Fundamental
79.4Momentum
n/aAcceleration
n/aConfidence
73.0Annual Revenue12
Quarterly Revenue37
Annual CFO9
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth25.0 / 25
Quality12.2 / 25
Capital Efficiency20.0 / 20
Balance Sheet14.1 / 15
Shareholder Economics4.1 / 10
Forward Indicators0.0 / 5
Signals
No positive signals calculated.
Warnings
Receivables anomaly · MEDIUMAccounts receivable growth is materially above revenue growth.
Heavy share dilution · HIGHDiluted share count increased 89.1198%.
Possible growth trap · HIGHRevenue growth is high, but quality indicators are deteriorating.
Key Metrics
Revenue Growth TTM5,932.37%OK
Revenue CAGR 3Y126.26%OK
Gross Marginn/aMISSING
Operating Margin85.85%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC97.04%OK
Incremental Operating Margin 3Y137.6%OK
Net Debt / CFO0.09xOK
Diluted Share Growth 1Y89.12%OK
SBC / Revenue0.67%OK
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $30.20M | $27.18M | $24.03M | -$1.18M | -$1.23M | 90% | 79.56% | -4.08% | 124.23% | 10.13M |
| 2025 FY Dec 31, 2024 | $5.20M | $5.09M | $324,717.00 | -$4.87M | n/a | 97.91% | 6.25% | n/a | 15.13% | 5.22M |
| 2024 FY Dec 31, 2023 | $3.42M | -$15.15M | -$30.75M | -$14.32M | -$15.12M | -443.23% | -899.53% | -442.32% | -1,543.95% | 787,832 |
| 2023 FY Dec 31, 2022 | $2.61M | -$712,293.00 | -$34.57M | -$20.45M | -$21.04M | -27.32% | -1,325.79% | -806.99% | n/a | 244,158 |
| 2022 FY Dec 31, 2021 | n/a | $1.29M | -$23.27M | -$21.48M | -$23.46M | n/a | n/a | n/a | n/a | 1.83M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $54.00M | sum latest 4 fiscal quarters Revenue | OK | 0001829126-26-006444, 0001829126-26-009079 |
| Revenue Growth TTM | 5,932.37% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001829126-26-006444, 0001829126-26-009079 |
| Revenue CAGR 3Y | 126.26% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001829126-26-005672 |
| Revenue CAGR 5Y | 48.27% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001829126-26-005672 |
| Gross Profit CAGR 3Y | n/a | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | INSUFFICIENT_HISTORY | 0001829126-26-005672 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001829126-26-006444, 0001829126-26-009079 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Margin | 85.85% | Operating Income / Revenue | OK | 0001829126-26-006444, 0001829126-26-009079 |
| CFO / Net Income | -0.04x | CFO / Net Income | OK | 0001829126-26-006444, 0001829126-26-009079 |
| ROIC | 97.04% | NOPAT / Average Invested Capital | OK | 0001829126-26-006444, 0001829126-26-009079 |
| Net Debt / CFO | 0.09x | Net Debt / CFO | OK | 0001829126-26-009079, 0001829126-26-006444 |
| Interest Coverage | 5,890.91x | Operating Income / abs(Interest Expense) | OK | derived |
| Current Ratio | 4.27x | Current Assets / Current Liabilities | OK | derived |
| SBC / Revenue | 0.67% | SBC / Revenue | OK | 0001829126-26-006444, 0001829126-26-009079 |